Cytosite Bio

Executive Summary

Cytosite Bio is a preclinical-stage biotechnology company revolutionizing immunotherapy by harnessing the power of granzyme B. Its platform aims to transform cancer and autoimmune disease treatments through two investigational product candidates: CSB-321 and CSB-421, which have not yet been approved by the FDA or other regulatory bodies. The company also develops a PET imaging radiodiagnostic to provide early mechanistic insights, potentially enabling biomarker-driven development. Despite its innovative approach, Cytosite remains in early preclinical stages with no disclosed funding rounds or valuation, indicating high risk but significant upside if its candidates succeed. The company's focus on granzyme B, a key immune effector molecule, positions it uniquely in the competitive cell therapy and oncology landscape.

Upcoming Catalysts (preview)

• TBDIND Filing for CSB-32170% success
• TBDFirst-in-Human Trial Initiation60% success
• TBDPreclinical Data Presentation at Major Conference80% success